ALNYLAM PHARMACEUTICALS, INC. Payments to Acquire Restricted Investments
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Payments to Acquire Restricted Investments of $22.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for the quarter ending 2025-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for the quarter ending 2025-09-30 was $1.70M, a 91.15% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for the quarter ending 2025-06-30 was $9.25M, a 48.32% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for the quarter ending 2025-03-31 was $48.83M, a 22.14% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for fiscal 2025 was $59.77M, a 22.45% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for fiscal 2024 was $77.08M, a 31.81% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for fiscal 2023 was $58.48M, a 40.60% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire restricted investments for fiscal 2022 was $98.45M, a 133.62% increase from fiscal 2021.
| Period end | Payments to Acquire Restricted Investments 3 month | Payments to Acquire Restricted Investments 6 month | Payments to Acquire Restricted Investments 9 month | Payments to Acquire Restricted Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.00M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.70M derived: sum of 2 quarters · filed 2026-02-12 | $10.95M derived: sum of 3 quarters · filed 2026-07-30 | $59.77M 10-K · filed 2026-02-12 |
| 2025-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $10.95M derived: sum of 2 quarters · filed 2026-07-30 | $59.77M 10-Q · filed 2025-10-30 | $59.77M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $9.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $58.08M 10-Q · filed 2026-07-30 | $58.08M derived: sum of 3 quarters · filed 2026-07-30 | $77.28M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $48.83M 10-Q · filed 2025-05-01 | $48.83M derived: sum of 2 quarters · filed 2026-02-12 | $68.03M derived: sum of 3 quarters · filed 2026-02-12 | $85.92M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $19.20M derived: sum of 2 quarters · filed 2026-02-12 | $37.10M derived: sum of 3 quarters · filed 2026-02-12 | $77.08M 10-K · filed 2026-02-12 |
| 2024-09-30 | $19.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $37.10M derived: sum of 2 quarters · filed 2025-10-30 | $77.08M 10-Q · filed 2025-10-30 | $77.08M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $17.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $57.88M 10-Q · filed 2025-07-31 | $57.88M derived: sum of 3 quarters · filed 2026-02-12 | $57.88M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $39.98M 10-Q · filed 2025-05-01 | $39.98M derived: sum of 2 quarters · filed 2026-02-12 | $39.98M derived: sum of 3 quarters · filed 2026-02-12 | $49.23M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $9.25M derived: sum of 3 quarters · filed 2026-02-12 | $58.48M 10-K · filed 2026-02-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $9.25M derived: sum of 2 quarters · filed 2024-10-31 | $58.48M 10-Q · filed 2024-10-31 | $58.48M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $9.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $58.48M 10-Q · filed 2024-08-01 | $58.48M derived: sum of 3 quarters · filed 2025-02-13 | $124.20M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $49.23M 10-Q · filed 2024-05-02 | $49.23M derived: sum of 2 quarters · filed 2025-02-13 | $114.95M derived: sum of 3 quarters · filed 2025-02-13 | $138.28M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $65.73M derived: sum of 2 quarters · filed 2025-02-13 | $89.05M derived: sum of 3 quarters · filed 2025-02-13 | $98.45M 10-K · filed 2025-02-13 |
| 2022-09-30 | $65.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $89.05M derived: sum of 2 quarters · filed 2023-11-02 | $98.45M 10-Q · filed 2023-11-02 | $114.45M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $23.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $32.73M 10-Q · filed 2023-08-03 | $48.73M derived: sum of 3 quarters · filed 2024-02-15 | $64.05M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $9.40M 10-Q · filed 2023-05-04 | $25.40M derived: sum of 2 quarters · filed 2024-02-15 | $40.73M derived: sum of 3 quarters · filed 2024-02-15 | $40.89M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $31.33M derived: sum of 2 quarters · filed 2024-02-15 | $31.49M derived: sum of 3 quarters · filed 2024-02-15 | $42.14M 10-K · filed 2024-02-15 |
| 2021-09-30 | $15.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $15.49M derived: sum of 2 quarters · filed 2022-10-27 | $26.14M 10-Q · filed 2022-10-27 | $42.14M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $10.81M 10-Q · filed 2021-08-03 | $26.82M derived: sum of 3 quarters · filed 2023-02-23 | $26.82M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $10.65M 10-Q · filed 2022-04-28 | $26.65M derived: sum of 2 quarters · filed 2023-02-23 | $26.65M derived: sum of 3 quarters · filed 2023-02-23 | $26.65M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $16.00M derived: sum of 2 quarters · filed 2023-02-23 | $16.00M derived: sum of 3 quarters · filed 2023-02-23 | $25.90M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $0.00 derived: sum of 2 quarters · filed 2021-10-28 | $9.90M 10-Q · filed 2021-10-28 | $9.90M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $9.90M 10-Q · filed 2021-08-03 | $9.90M derived: sum of 3 quarters · filed 2022-02-10 | $9.90M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $9.90M 10-Q · filed 2021-04-29 | $9.90M derived: sum of 2 quarters · filed 2022-02-10 | $9.90M derived: sum of 3 quarters · filed 2022-02-10 | $9.90M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $0.00 derived: sum of 2 quarters · filed 2022-02-10 | $0.00 derived: sum of 3 quarters · filed 2022-02-10 | $0.00 10-K · filed 2022-02-10 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-02-11 | $0.00 derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $0.00 derived: sum of 3 quarters · filed 2021-02-11 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $14.82M 10-K · filed 2021-02-11 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $14.82M 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $14.82M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $150.00M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |